Finally, given the broad impact of RT/αPD-L1 on the PD-1+ TCF-1+ subset in the TdLN, we evaluated whether this subset was required for the enhanced tumor control observed with combination therapy. The gene discussed is PDCD1; the disease is neoplasm.